HRP20182017T4 - Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use - Google Patents

Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use Download PDF

Info

Publication number
HRP20182017T4
HRP20182017T4 HRP20182017TT HRP20182017T HRP20182017T4 HR P20182017 T4 HRP20182017 T4 HR P20182017T4 HR P20182017T T HRP20182017T T HR P20182017TT HR P20182017 T HRP20182017 T HR P20182017T HR P20182017 T4 HRP20182017 T4 HR P20182017T4
Authority
HR
Croatia
Prior art keywords
antigen
binding fragment
antibody
seq
alpha toxin
Prior art date
Application number
HRP20182017TT
Other languages
Croatian (hr)
Inventor
Bret SELLMAN
Christine TKACZYK
Lei Hua
Partha Chowdhury
Reena VARKEY
Melissa Damschroder
Li Peng
Vaheh Oganesyan
Jamese Johnson Hilliard
Original Assignee
Medimmune, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46639171&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20182017(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medimmune, Llc filed Critical Medimmune, Llc
Publication of HRP20182017T1 publication Critical patent/HRP20182017T1/en
Publication of HRP20182017T4 publication Critical patent/HRP20182017T4/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56938—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/305—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F)
    • G01N2333/31—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/44—Multiple drug resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/709—Toxin induced
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Claims (17)

1. Izolirano protutijelo ili njegov ulomak koji veže antigen, naznačeno time što se izolirano protutijelo ili njegov ulomak koji veže antigen imunospecifično veže na polipeptid alfa toksina koji stvara Staphylococcus aureus i sadrži: (a) VH CDR1 sadrži sekvencu aminokiseline iz SEQ ID NO: 69; (b) VH CDR2 sadrži sekvencu aminokiseline iz SEQ ID NO: 70; (c) VH CDR3 sadrži sekvencu aminokiseline iz SEQ ID NO: 71; (d) VL CDR1 sadrži sekvencu aminokiseline iz SEQ ID NO: 1; (e) VL CDR2 sadrži sekvencu aminokiseline iz SEQ ID NO: 2, i (f) VL CDR3 sadrži sekvencu aminokiseline iz SEQ ID NO: 68 .1. An isolated antibody or an antigen-binding fragment thereof, characterized in that the isolated antibody or an antigen-binding fragment thereof binds immunospecifically to the alpha toxin polypeptide produced by Staphylococcus aureus and contains: (a) VH CDR1 comprises the amino acid sequence of SEQ ID NO: 69; (b) VH CDR2 comprises the amino acid sequence of SEQ ID NO: 70; (c) VH CDR3 comprises the amino acid sequence of SEQ ID NO: 71; (d) VL CDR1 comprises the amino acid sequence of SEQ ID NO: 1; (e) VL CDR2 comprises the amino acid sequence of SEQ ID NO: 2, i (f) VL CDR3 contains the amino acid sequence of SEQ ID NO: 68. 2. Izolirano protutijelo ili ulomak koji veže antigen prema zahtjevu 1, naznačeno time što sadrži varijabilnu domenu teškog lanca koja je barem 90% identična s aminokiselinskom sekvencom iz SEQ ID NO: 57, i varijabilnu domenu laganog lanca koja je barem 90% identična sa aminokiselinskom sekvencom iz SEQ ID NO: 58.2. An isolated antibody or antigen-binding fragment according to claim 1, characterized in that it contains a heavy chain variable domain that is at least 90% identical to the amino acid sequence from SEQ ID NO: 57, and a light chain variable domain that is at least 90% identical to the amino acid sequence with the sequence from SEQ ID NO: 58. 3. Protutijelo ili ulomak koji veže antigen prema zahtjevu 2, naznačeno time što VH i VL odgovaraju sekvencama aminokiselina iz SEQ ID NO: 57 i 58.3. Antibody or antigen-binding fragment according to claim 2, characterized in that VH and VL correspond to amino acid sequences from SEQ ID NO: 57 and 58. 4. Protutijelo ili ulomak koji veže antigen prema bilo kojem od zahtjeva 1 do 3, naznačeno time što izolirano protutijelo ili njegov ulomak koji veže antigen ima jednu ili više značajki odabranih iz skupine koju čine: (a) konstanta afiniteta (KD) za alfa toksin od oko 13 nM ili manje; (b) veže se na monomere alfa toksina, ali ne inhibira vezanje alfa toksina na receptor alfa toksina; (c) inhibira stvaranje oligomera alfa toksina za barem 50%, 60%, 70%, 80%, 90%, ili 95%; (d) smanjuje citolitičku aktivnost alfa toksina za barem 50%, 60%, 70%, 80%, 90%, ili 95% (npr.., određeno pomoću testova lize stanice i hemolize stanice); i (e) smanjuje infiltraciju stanica i pro-upalno oslobađanje citokina (npr., u modelu životinjske upale pluća).4. Antibody or antigen-binding fragment according to any one of claims 1 to 3, characterized in that the isolated antibody or antigen-binding fragment thereof has one or more features selected from the group consisting of: (a) an affinity constant (KD) for the alpha toxin of about 13 nM or less; (b) binds to alpha toxin monomers but does not inhibit alpha toxin binding to the alpha toxin receptor; (c) inhibits alpha toxin oligomer formation by at least 50%, 60%, 70%, 80%, 90%, or 95%; (d) reduces the cytolytic activity of the alpha toxin by at least 50%, 60%, 70%, 80%, 90%, or 95% (eg, determined by cell lysis and cell hemolysis assays); and (e) reduces cell infiltration and pro-inflammatory cytokine release (eg, in an animal model of lung inflammation). 5. Pripravak naznačen time što sadrži protutijelo ili ulomak koji veže antigen prema bilo kojem od zahtjeva 1 do 4.5. A preparation characterized in that it contains an antibody or an antigen-binding fragment according to any one of claims 1 to 4. 6. Pripravak prema zahtjevu 5, naznačen time što pripravak sadrži dodatno sredstvo, pri čemu je dodatno sredstvo antibiotik.6. The preparation according to claim 5, characterized in that the preparation contains an additional agent, wherein the additional agent is an antibiotic. 7. Komplet, naznačen time što sadrži (a) protutijelo ili ulomak koji veže antigen prema bilo kojem od zahtjeva 1 do 4 ili pripravak prema zahtjevu ili 6; (b) upute za uporabu pripravka ili smjernice za dobivanje uputa za uporabu pripravka.7. The set, indicated by what it contains (a) an antibody or antigen-binding fragment according to any of claims 1 to 4 or a preparation according to claim or 6; (b) instructions for use of the preparation or guidelines for obtaining instructions for use of the preparation. 8. Protutijelo ili ulomak koji veže antigen prema bilo kojem od zahtjeva 1 do 4 ili pripravak prema zahtjevu 5 ili 6, naznačeno time što je za uporabu za prevenciju, liječenje ili upravljanje upalom pluća kod subjekta.8. An antibody or antigen-binding fragment according to any one of claims 1 to 4 or a composition according to claim 5 or 6, for use in the prevention, treatment or management of pneumonia in a subject. 9. Protutijelo ili ulomak koji veže antigen prema bilo kojem od zahtjeva 1 do 4 ili pripravak prema zahtjevu 5 ili 6, naznačeno time što je za uporabu za prevenciju, liječenje ili upravljanje stanjem infekcije kože kod subjekta.9. An antibody or antigen-binding fragment according to any one of claims 1 to 4 or a composition according to claim 5 or 6, characterized in that it is for use in the prevention, treatment or management of a skin infection condition in a subject. 10. Protutijelo ili ulomak koji veže antigen prema bilo kojem od zahtjeva 1 do 4 ili pripravak prema zahtjevu 5 ili 6, naznačeno time što je za uporabu za prevenciju, liječenje ili upravljanje upalom pluća ili stanjem infekcije kože kod subjekta prema zahtjevu 8 ili 9 inhibicijom stvaranja oligomera alfa toksina Staphylococcus aureus za barem 50%, 60%, 70%, 80%, 90% ili 95%.10. An antibody or antigen-binding fragment according to any one of claims 1 to 4 or a preparation according to claim 5 or 6, characterized in that it is for use in preventing, treating or managing pneumonia or a skin infection condition in a subject according to claim 8 or 9 by inhibiting of Staphylococcus aureus alpha toxin oligomer formation by at least 50%, 60%, 70%, 80%, 90% or 95%. 11. Protutijelo ili ulomak koji veže antigen prema bilo kojem od zahtjeva 1 do 4 naznačeno time što se imuno specifično veže na ulomak alfa toksina koji stvara Staphylococcus aureus iz SEQ ID NO: 39.11. The antibody or antigen-binding fragment according to any one of claims 1 to 4 characterized in that it immunospecifically binds to the alpha toxin fragment produced by Staphylococcus aureus of SEQ ID NO: 39. 12. Izolirano protutijelo ili ulomak koji veže antigen prema zahtjevu 11, naznačeno time što se protutijelo ili njegov ulomak koji veže antigen veže na ulomak koji sadrži aminokiseline 261-272 iz SEQ ID NO: 39 i/ili aminokiseline 173-201 iz SEQ ID NO: 39.12. Isolated antibody or antigen-binding fragment according to claim 11, characterized in that the antibody or its antigen-binding fragment binds to a fragment containing amino acids 261-272 from SEQ ID NO: 39 and/or amino acids 173-201 from SEQ ID NO : 39. 13. Izolirano protutijelo ili ulomak koji veže antigen prema zahtjevu 12, naznačeno time što se protutijelo ili njegov ulomak koji veže antigen veže se na ulomak koji sadrži aminokiseline 261-272 iz SEQ ID NO: 39 i aminokiseline 173-201 iz SEQ ID NO: 39.13. Isolated antibody or antigen-binding fragment according to claim 12, characterized in that the antibody or its antigen-binding fragment binds to a fragment containing amino acids 261-272 from SEQ ID NO: 39 and amino acids 173-201 from SEQ ID NO: 39. 14. Izolirano protutijelo ili ulomak koji veže antigen prema bilo kojem od zahtjeva 1 do 4, naznačeno time što protutijelo ili njegov ulomak koji veže antigen sprječava nastanak heptamera alfa toksina, i pri čemu je navedeno protutijelo ili ulomak koji veže antigen u kontaktu s ostacima na položajima T261, T263, N264, K266, K271, N177, W179, G180, P181, Y182, D183, D185, S186, W187, N188, P189, V190, Y191 i R200 od SEQ ID NO: 39.14. An isolated antibody or antigen-binding fragment according to any one of claims 1 to 4, characterized in that the antibody or antigen-binding fragment thereof prevents the formation of alpha toxin heptamers, and wherein said antibody or antigen-binding fragment is in contact with residues on positions T261, T263, N264, K266, K271, N177, W179, G180, P181, Y182, D183, D185, S186, W187, N188, P189, V190, Y191 and R200 of SEQ ID NO: 39. 15. Pripravak prema zahtjevu 6, naznačen time što je antibiotik vankomicin.15. The preparation according to claim 6, characterized in that the antibiotic is vancomycin. 16. Izolirano protutijelo ili ulomak koji veže antigen prema bilo kojem od zahtjeva 11 do 14 naznačeno time što je za uporabu za prevenciju, liječenje ili upravljanje upalom pluća ili stanjem infekcije kože kod subjekta inhibicijom stvaranja oligomera alfa toksina.16. An isolated antibody or antigen-binding fragment according to any one of claims 11 to 14 for use in preventing, treating or managing a pneumonia or skin infection condition in a subject by inhibiting alpha toxin oligomer formation. 17. Izolirano protutijelo ili ulomak koji veže antigen prema bilo kojem od zahtjeva 1-4 i 11-14 koje obuhvaća varijantu Fc regije, naznačeno time što izolirano protutijelo sadrži slijedeće sekvence [image] i [image] 17. An isolated antibody or antigen-binding fragment according to any of claims 1-4 and 11-14 comprising a variant of the Fc region, characterized in that the isolated antibody contains the following sequences [image] and [image]
HRP20182017TT 2011-02-08 2018-11-29 Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use HRP20182017T4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161440581P 2011-02-08 2011-02-08
EP12745207.6A EP2673373B3 (en) 2011-02-08 2012-02-07 Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use
PCT/US2012/024201 WO2012109285A2 (en) 2011-02-08 2012-02-07 Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use

Publications (2)

Publication Number Publication Date
HRP20182017T1 HRP20182017T1 (en) 2019-02-08
HRP20182017T4 true HRP20182017T4 (en) 2021-08-20

Family

ID=46639171

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20182017TT HRP20182017T4 (en) 2011-02-08 2018-11-29 Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use

Country Status (24)

Country Link
US (1) US9527905B2 (en)
EP (2) EP2673373B3 (en)
JP (4) JP2014508748A (en)
KR (1) KR101993839B1 (en)
CN (2) CN107474133B (en)
AU (1) AU2012214531C1 (en)
BR (1) BR112013020086B1 (en)
CA (1) CA2826566C (en)
CY (1) CY1121389T1 (en)
DK (1) DK2673373T6 (en)
ES (1) ES2709065T7 (en)
HK (1) HK1248257A1 (en)
HR (1) HRP20182017T4 (en)
HU (1) HUE040734T2 (en)
LT (1) LT2673373T (en)
MX (2) MX345285B (en)
PL (1) PL2673373T6 (en)
PT (1) PT2673373T (en)
RS (1) RS58190B2 (en)
RU (1) RU2620065C2 (en)
SG (3) SG10201600899PA (en)
SI (1) SI2673373T1 (en)
TR (1) TR201817932T4 (en)
WO (1) WO2012109285A2 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE038509T2 (en) 2011-06-10 2018-10-29 Medimmune Ltd Anti-pseudomonas psl binding molecules and uses thereof
CA3161431A1 (en) 2011-11-07 2013-05-16 Medimmune Limited Combination therapies using anti-pseudomonas psl and pcrv binding molecules
US9988439B2 (en) 2011-12-23 2018-06-05 Nicholas B. Lydon Immunoglobulins and variants directed against pathogenic microbes
EP2793944A4 (en) 2011-12-23 2015-09-02 Nicholas B Lydon Immunoglobulins and variants directed against pathogenic microbes
JOP20200236A1 (en) * 2012-09-21 2017-06-16 Regeneron Pharma Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
RU2661406C2 (en) * 2012-11-06 2018-07-16 МЕДИММЬЮН, ЭлЭлСи Methods of treating s. aureus-associated diseases
CN104995209A (en) * 2012-11-06 2015-10-21 米迪缪尼有限公司 Combination therapies using anti-pseudomonas psl and pcrv binding molecules
BR112015010125A2 (en) * 2012-11-06 2017-08-22 Medimmune Llc ISOLATED ANTIBODY OR ITS BINDING FRAGMENT, COMPOSITION, ISOLATED NUCLEIC ACID, METHODS OF DETERMINING THE PRESENCE OF S. AUREUS IN A TEST SAMPLE, TREATMENT OF AN INFECTION BY S. AUREUS IN A PATIENT, PREVENTION OR REDUCING THE SEVERITY OF SEPSIA ASSOCIATED WITH S. AUREUS IN A PATIENT, DELAYING THE START OF SEPSIA ASSOCIATED WITH S. AUREUS INFECTION IN A PATIENT, PREVENTION OF THE START OF SEPSIA ASSOCIATED WITH S. AUREUS INFECTION IN A PATIENT, REDUCING THE BACTERIAL LOAD OF S. AUREUS aureus in the blood stream or heart in a patient, and reduction of bacterial agglutination of S. aureus and/or formation of thromboembolic lesions in a patient
BR112016008275A2 (en) * 2013-10-17 2017-10-03 Arsanis Biosciences Gmbh ANTIBODY WITH CROSS-REACTIVITY TO STAPHYLOCOCCUS AUREUS, PHARMACEUTICAL OR DIAGNOSTIC PREPARATIONS COMPRISING THE ANTIBODY, ANTIBODY FOR MEDICAL AND DIAGNOSTIC USE, AN ISOLATED NUCLEIC ACID ENCODING ANTIBODY, PLASMID OR EXPRESSION CASSETTE, AND PLASMID OR CASSETTE HOST CELL COMPRISING CASMID OR CASSETTE HOST CELL , METHOD FOR PRODUCING THE ANTIBODY USING SUCH A HOST CELL, METHOD FOR PRODUCING ANTIBODY VARIANTS, A CRYSTAL FORMED BY AN HLA OR LUKD MONOMER WITH SAID ANTIBODY, A PARATOPE ISOLATED FROM THE ANTIBODY, THE ISOLATED Epitope AND A BINDING MOLECULE SPECIFICALLY BINDING TO SAID Epitope, a screening method for identifying a ligand that binds to said epitope, an immunogen comprising said epitope, and said immunogen used to induce a protective immune response
JP2017504325A (en) * 2014-01-14 2017-02-09 インテグレイテッド バイオセラピューティクス，インコーポレイテッド Method for targeting immunological function to bacterial infection site using cell wall targeting domain of bacteriocin
TWI701042B (en) 2014-03-19 2020-08-11 美商再生元醫藥公司 Methods and antibody compositions for tumor treatment
TWI719938B (en) * 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 Treatment of polybacterial infections
WO2016023943A1 (en) * 2014-08-12 2016-02-18 Arsanis Biosciences Gmbh Predicting s. aureus disease
WO2016081490A1 (en) 2014-11-17 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods for tumor treatment using cd3xcd20 bispecific antibody
JP6889701B2 (en) * 2015-09-24 2021-06-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Alpha hemolysin variant
WO2017075188A2 (en) * 2015-10-30 2017-05-04 Medimmune, Llc Methods of using anti-alpha toxin antibody
TW202311284A (en) 2017-01-03 2023-03-16 美商再生元醫藥公司 Human antibodies to s. aureus hemolysin a toxin
EP3580239A4 (en) 2017-02-09 2021-07-28 Bluefin Biomedicine, Inc. Anti-ilt3 antibodies and antibody drug conjugates
CN109384844B (en) * 2017-08-04 2020-12-18 中国人民解放军军事医学科学院基础医学研究所 Anti-staphylococcus aureus alpha hemolysin monoclonal antibody and application thereof
BR112021001214A2 (en) 2018-07-24 2021-04-27 Medimmune, Llc antibody directed against the agglutination factor a (cfa) of s. aureus
WO2020041532A1 (en) * 2018-08-21 2020-02-27 Sf17 Therapeutics, Inc. Compositions and methods for treating progressive neurodegenerative diseases
EP3844189A1 (en) 2018-08-31 2021-07-07 Regeneron Pharmaceuticals, Inc. Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies
TW202035443A (en) 2018-10-09 2020-10-01 美商麥迪紐有限責任公司 Combinations of anti-staphylococcus aureus antibodies
CA3115765A1 (en) 2018-10-09 2020-04-16 Medimmune, Llc Antibodies directed against staphylococcus aureus leukotoxins
TW202100549A (en) * 2019-03-13 2021-01-01 美商麥迪紐有限責任公司 Decreasing staphylococcus aureus infections in colonized patients
WO2020210650A1 (en) 2019-04-12 2020-10-15 Medimmune, Llc Neutralization of tgf-beta or alpha-v-beta-8 integrin for s. aureus infections
CN112538112B (en) 2019-09-20 2023-10-27 迈威(上海)生物科技股份有限公司 Antibodies against alpha-hemolysin and uses thereof
CN113444173A (en) 2020-03-25 2021-09-28 兴盟生物医药(苏州)有限公司 Staphylococcus aureus alpha-toxin specific antibody and application thereof
CN112941136B (en) * 2021-03-24 2023-04-28 成都欧林生物科技股份有限公司 Purification method of recombinant staphylococcus aureus vaccine HI antigen protein
CN114455048B (en) * 2022-03-02 2023-03-14 江苏微导纳米科技股份有限公司 Paddle rod
WO2023208123A1 (en) * 2022-04-28 2023-11-02 珠海泰诺麦博制药股份有限公司 Fully human monoclonal antibody specifically binding to staphylococcus aureus hla toxin
CN116589566A (en) * 2022-11-18 2023-08-15 昆明医科大学第一附属医院 Modified recombinant monoclonal IgM antibody of HIV-1 neutralizing antibody and application thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
ES2206447T3 (en) 1991-06-14 2004-05-16 Genentech, Inc. HUMANIZED ANTIBODY FOR HEREGULINE.
CA2253710A1 (en) 1996-04-25 1997-10-30 Spectrametrix Inc. Analyte assay using particulate labels
KR100787073B1 (en) 2000-06-28 2007-12-21 글리코파이, 인크. Methods for producing modified glycoproteins
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
EP2341060B1 (en) 2000-12-12 2019-02-20 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US20030226155A1 (en) * 2001-08-30 2003-12-04 Biorexis Pharmaceutical Corporation Modified transferrin-antibody fusion proteins
EP1479695B1 (en) 2003-05-14 2010-02-17 Kenta Biotech AG Human monoclonal antibody specific for lipopolysaccharides (LPS) of serotype IATS O6 of Pseudomonas aeruginosa
CN1324049C (en) 2003-08-04 2007-07-04 中国疾病预防控制中心病毒病预防控制所 Human source anti SARS coronavirus gene engineering antibody
CA2885854C (en) 2004-04-13 2017-02-21 F. Hoffmann-La Roche Ag Anti-p-selectin antibodies
EP1793849A2 (en) * 2004-09-22 2007-06-13 GlaxoSmithKline Biologicals SA Immunogenic composition for use in vaccination against staphylococcei
KR20080094064A (en) 2006-01-17 2008-10-22 바이오렉스 쎄라퓨틱스, 인코포레이티드 Compositions and methods for humanization and optimization of n-glycans in plants
TW200813091A (en) * 2006-04-10 2008-03-16 Amgen Fremont Inc Targeted binding agents directed to uPAR and uses thereof
NZ597046A (en) * 2006-06-12 2014-01-31 Glaxosmithkline Biolog Sa Use of alpha-toxin for treating and preventing staphylococcus infections
US20100166772A1 (en) * 2007-05-31 2010-07-01 Anderson Annaliesa S ANTIGEN-BINDING PROTEINS TARGETING S. AUREUS ORF0657n
CL2008002444A1 (en) 2007-08-21 2009-09-04 Amgen Inc Antibody or fragment thereof that binds to human c-fms protein; nucleic acid molecule that encodes it; vector and host cell; production method; pharmaceutical composition comprising it; and its use to treat or prevent a condition associated with c-fms in a patient.
EP2185190B1 (en) 2007-08-31 2015-06-24 University Of Chicago Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
US8172115B1 (en) 2008-04-10 2012-05-08 Spencer Forrest, Inc. Hair building solids dispenser for one handed operation
BRPI0914005A2 (en) * 2008-07-02 2015-11-17 Emergent Product Dev Seattle multi-target tnf-alpha antagonist proteins
EP2208787A1 (en) * 2009-01-19 2010-07-21 Université de Liège A recombinant alpha-hemolysin polypeptide of Staphylococcus aureus, having a deletion in the stem domain and heterologous sequences inserted
GB2467939A (en) * 2009-02-20 2010-08-25 Univ Sheffield Removal of bacteria from media
MX2012000044A (en) * 2009-06-22 2012-01-30 Wyeth Llc Immunogenic compositions of staphylococcus aureus antigens.
BR112015010125A2 (en) 2012-11-06 2017-08-22 Medimmune Llc ISOLATED ANTIBODY OR ITS BINDING FRAGMENT, COMPOSITION, ISOLATED NUCLEIC ACID, METHODS OF DETERMINING THE PRESENCE OF S. AUREUS IN A TEST SAMPLE, TREATMENT OF AN INFECTION BY S. AUREUS IN A PATIENT, PREVENTION OR REDUCING THE SEVERITY OF SEPSIA ASSOCIATED WITH S. AUREUS IN A PATIENT, DELAYING THE START OF SEPSIA ASSOCIATED WITH S. AUREUS INFECTION IN A PATIENT, PREVENTION OF THE START OF SEPSIA ASSOCIATED WITH S. AUREUS INFECTION IN A PATIENT, REDUCING THE BACTERIAL LOAD OF S. AUREUS aureus in the blood stream or heart in a patient, and reduction of bacterial agglutination of S. aureus and/or formation of thromboembolic lesions in a patient

Also Published As

Publication number Publication date
JP6723293B2 (en) 2020-07-15
CN103443285B9 (en) 2018-04-24
JP2020172489A (en) 2020-10-22
RU2013141134A (en) 2015-03-20
MX2013009127A (en) 2014-01-31
TR201817932T4 (en) 2019-02-21
RS58190B2 (en) 2021-08-31
SG10201600899PA (en) 2016-03-30
CA2826566C (en) 2022-09-13
EP2673373A2 (en) 2013-12-18
PL2673373T3 (en) 2019-04-30
EP2673373B3 (en) 2021-06-02
LT2673373T (en) 2019-01-25
CN107474133B (en) 2021-10-15
RU2620065C2 (en) 2017-05-22
JP6367393B2 (en) 2018-08-01
SI2673373T1 (en) 2019-03-29
MX345285B (en) 2017-01-24
CN103443285B (en) 2017-06-23
BR112013020086A2 (en) 2016-11-22
ES2709065T3 (en) 2019-04-15
RS58190B1 (en) 2019-03-29
AU2012214531C1 (en) 2021-07-29
CY1121389T1 (en) 2020-05-29
KR20140019344A (en) 2014-02-14
JP2019011329A (en) 2019-01-24
US20140072577A1 (en) 2014-03-13
HK1248257A1 (en) 2018-10-12
AU2012214531B2 (en) 2017-03-16
SG192212A1 (en) 2013-09-30
EP2673373B1 (en) 2018-08-29
CN107474133A (en) 2017-12-15
KR101993839B1 (en) 2019-06-28
CN103443285A (en) 2013-12-11
CA2826566A1 (en) 2012-08-16
EP2673373A4 (en) 2015-06-17
HRP20182017T1 (en) 2019-02-08
EP3470526A3 (en) 2019-07-17
EP3470526A2 (en) 2019-04-17
JP2017128575A (en) 2017-07-27
DK2673373T6 (en) 2021-08-23
WO2012109285A3 (en) 2012-10-04
PT2673373T (en) 2018-12-05
WO2012109285A2 (en) 2012-08-16
PL2673373T6 (en) 2021-09-27
BR112013020086B1 (en) 2020-12-08
ES2709065T7 (en) 2021-12-09
US9527905B2 (en) 2016-12-27
DK2673373T3 (en) 2019-01-02
JP2014508748A (en) 2014-04-10
SG10201913690SA (en) 2020-03-30
HUE040734T2 (en) 2019-03-28
MX2020009700A (en) 2020-10-07
JP7047017B2 (en) 2022-04-04

Similar Documents

Publication Publication Date Title
HRP20182017T4 (en) Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use
JP2014508748A5 (en)
HRP20200745T1 (en) Cd123 binding agents and uses thereof
JP2020037555A5 (en)
HRP20181087T1 (en) Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
JP2021063090A5 (en)
HRP20191608T1 (en) Dipeptide-repeat proteins as therapeutic target in neurodegenerative diseases with hexanucleotide repeat expansion
JP2009225799A5 (en)
HRP20190917T1 (en) Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile
RU2016100892A (en) ANTIBODIES AGAINST TWEAKR AND THEIR APPLICATION
ES2776179T3 (en) Antibodies directed against surface determinants of S. aureus
JP2015504421A5 (en)
RU2015121617A (en) METHODS FOR TREATING DISEASES ASSOCIATED WITH S. AUREUS
RU2571204C3 (en) SPECIFIC BINDING AGENTS AGAINST B7-H1
TR201809128T4 (en) Compounds that bind specifically to gram-positive bacteria.
JP2012511329A5 (en)
JP2009518005A5 (en)
JP2014533239A5 (en)
JP2011509245A5 (en)
SI2514436T1 (en) Il-22 for use in treating microbial disorders
JP2015533795A5 (en)
JP2019031567A5 (en)
SI2857418T1 (en) Antibodies against Clostridium difficile toxins and uses thereof
HRP20191277T1 (en) Anti-cd26 antibodies and uses thereof
JP2016136963A5 (en)